Reaction

Type I Hypersensitivity reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,449 reports · 76 co-occurring drugs

As of the last recalculation, Type I Hypersensitivity appears in 3,449 FAERS reports alongside 76 co-occurring drug terms. The strongest observed disproportionality signal is AMOXICILLIN (PRR 34.8).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Amoxicillin	392	34.8	35.0
Oxaliplatin	268	23.6	23.6
Cefazolin Sodium	41	20.8	20.8
Levofloxacin	188	19.8	19.9
Levofloxacin In 5% Dextrose	188	19.8	19.9
Cefazolin	28	18.7	18.7
Cefuroxime	34	18.1	18.2
Rocuronium Bromide	35	18.1	18.2
Propofol	105	17.9	17.9
Ketoprofen	35	16.3	16.3
Cetiirizine	86	12.5	12.6
Ampicillin	14	10.2	10.3
Ampicillin Sodium	14	10.2	10.3
Rifampin	23	9.6	9.6
Paclitaxel (Aibumin-Bound)	112	8.5	8.5
Lidocaine Hydrochloride And Epinephrine Bitartrate	70	8.1	8.1
Sevoflurane	11	8.0	8.0
Diclofenac	111	8.0	8.0
Desloratadine	14	7.9	7.9
Isoniazid	21	7.9	7.9
Cephalexin	28	7.9	7.9
Lidicaine	62	7.8	7.8
Burn Relief	62	7.8	7.8
Lidocaine Hydrochloride And Epinephrine	62	7.8	7.8
Lidocaine, Menthol	62	7.7	7.7
Carboplatin	154	7.6	7.6
Methylprednisolone Acetate	10	7.6	7.6
Lidocaine Hydrochloride	74	7.5	7.6
Cetirizine	94	7.5	7.5
Lidocaine 4%	64	7.2	7.2
Paclitaxel	114	7.2	7.2
Pyrazinamide	11	7.1	7.1
Clindamycin	33	7.1	7.1
Triamcinolone Acetonide Ointment Usp, 0.05%	27	7.0	7.0
Methylprednisolone Sodium Succinate	52	6.8	6.9
Lidocaine	64	6.7	6.7
Amoxicillin And Clavulanate Potassium	30	6.7	6.7
Ceftriaxone	34	6.3	6.3
Clindamycin Phosphate	34	6.2	6.2
Ceftriaxone Sodium	38	6.0	6.0
Moxifloxacin	14	6.0	6.0
Ondansetron	105	5.9	6.0
Ondansetron Tablets	105	5.9	6.0
Ondansetron Hydrochloride	110	5.6	5.6
Leucovorin Calcium	17	5.4	5.4
Triamcinolone Acetonide	27	5.3	5.3
Fosaprepitant Dimeglumine	12	5.3	5.3
Erythromycin	16	5.2	5.2
Diclofenac Sodium	124	5.1	5.1
Diclofenac Sodium 1%	30	5.1	5.1
Diclofenac Sodium Topical	30	5.1	5.1
Iohexol	7	5.1	5.1
Diclofenac Sodium Topical Gel, 1%	30	5.1	5.1
Panitumumab	13	5.0	5.0
Midazolam	20	4.8	4.8
Midazolam Hydrochloride	21	4.7	4.7
Metronidazole Topical	36	4.6	4.6
Aprepitant	14	4.6	4.6
Famotidine	82	4.3	4.3
Rifampicin	7	4.2	4.2
Insulin Glulisine	7	4.2	4.2
Omalizumab	57	4.1	4.1
Tranexamic Acid	6	4.1	4.1
Bupivacaine	6	3.9	3.9
Mesna Injection	5	3.7	3.7
Mesna	5	3.6	3.6
Brentuximab Vedotin	6	3.5	3.5
Gemcitabine	22	3.4	3.4
Fluorouracil Cream, 0.5%	39	3.1	3.1
Fluorouracil	39	3.1	3.1
Irinotecan Hydrochloride	6	2.8	2.8
Gemcitabine Hydrochloride	22	2.5	2.5
Docetaxel Anhydrous	26	2.3	2.3
Docetaxel	26	2.3	2.3
Pemetrexed	8	2.3	2.3
Erenumab-Aooe	11	1.2	1.2

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.